Antibody therapies for the treatment of COVID-19
The outbreak of COVID-19, the disease caused by infection of the coronavirus SARS-CoV-2
that began in December 2019 in Wuhan, China, has caused more than 2 990 559 confirmed …
that began in December 2019 in Wuhan, China, has caused more than 2 990 559 confirmed …
The immunology of SARS-CoV-2 infection, the potential antibody based treatments and vaccination strategies
Z Payandeh, N Mohammadkhani… - Expert review of anti …, 2021 - Taylor & Francis
Introduction: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) as a
potentially fatal agent for a new emerging viral disease (COVID-19) is of great global public …
potentially fatal agent for a new emerging viral disease (COVID-19) is of great global public …
The landscape of neutralizing monoclonal antibodies (nAbs) for treatment and prevention of COVID-19
A de Almeida Oliveira, D Praia Borges Freire… - Journal of …, 2023 - Springer
Purpose After nearly 3 years of the COVID-19 pandemic, even though a vast body of
knowledge and products (including vaccines and treatments) have been developed and …
knowledge and products (including vaccines and treatments) have been developed and …
Neutralizing monoclonal antibodies against highly pathogenic coronaviruses
R Xiang, Y Wang, L Wang, X Deng, S Huo… - Current Opinion in …, 2022 - Elsevier
The pandemic of Coronavirus Disease 2019 (COVID-19) caused by severe acute respiratory
syndrome 2 coronavirus (SARS-CoV-2) is a continuing worldwide threat to human health …
syndrome 2 coronavirus (SARS-CoV-2) is a continuing worldwide threat to human health …
Anti-SARS-CoV-2 vaccines and monoclonal antibodies facing viral variants
A Chaqroun, C Hartard, E Schvoerer - Viruses, 2021 - mdpi.com
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is genetically variable,
allowing it to adapt to various hosts including humans. Indeed, SARS-CoV-2 has …
allowing it to adapt to various hosts including humans. Indeed, SARS-CoV-2 has …
Clonal wars: monoclonal antibodies against infectious pathogens
J Tan - DNA and Cell Biology, 2022 - liebertpub.com
Monoclonal antibodies are coming of age as powerful tools for the prevention of infectious
diseases. In recent years, the rate of antibody discovery has accelerated, and the …
diseases. In recent years, the rate of antibody discovery has accelerated, and the …
Perspectives on the use and risk of adverse events associated with cytokine-storm targeting antibodies and challenges associated with development of novel …
AM Johnson, R Barigye… - Human Vaccines & …, 2021 - Taylor & Francis
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent
of the novel coronavirus disease 2019 (COVID-19) pandemic that lacks globally accessible …
of the novel coronavirus disease 2019 (COVID-19) pandemic that lacks globally accessible …
Monoclonal antibody therapies in the management of SARS-CoV-2 infection
E Miguez-Rey, D Choi, S Kim, S Yoon… - Expert Opinion on …, 2022 - Taylor & Francis
ABSTRACT Introduction Neutralizing antibodies (NAbs) that target key domains of the spike
protein in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) may have …
protein in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) may have …
Broadly-neutralizing antibodies against emerging SARS-CoV-2 variants
The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants
have become a major concern in the containment of current pandemic. The variants …
have become a major concern in the containment of current pandemic. The variants …
Single center experience using monoclonal COVID-19 antibodies in the management of immunocompromised patients with COVID-19
The medical care of immunocompromised patients with COVID-19 infection causes major
hurdles in the management of these patients in clinical practice. However, poor responses to …
hurdles in the management of these patients in clinical practice. However, poor responses to …